LPA receptor antagonists and uses thereof
US-11702407-B2 · Jul 18, 2023 · US
Lpa receptor antagonists and uses thereof
US2024002367A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2024002367-A1 |
| Application number | US-202318322890-A |
| Country | US |
| Kind code | A1 |
| Filing date | May 24, 2023 |
| Priority date | Jun 3, 2020 |
| Publication date | Jan 4, 2024 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
First claim
Opening claim text (preview).
1 - 56 . (canceled) 57 . A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 58 - 60 . (canceled) 61 . The compound or pharmaceutically acceptable salt thereof of claim 57 , wherein the compound is 62 . A pharmaceutical composition comprising a therapeutically effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 57 , and a pharmaceutically acceptable excipient. 63 . (canceled) 64 . A method of treating, stabilizing, or lessening the severity or progression of an LPAR1 mediated disease or condition comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 57 , or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 62 . 65 - 98 . (canceled)
Assignees
Inventors
Classifications
- C07D403/10Primary
linked by a carbon chain containing aromatic rings · CPC title
linked by a carbon chain containing aromatic rings · CPC title
containing three or more hetero rings · CPC title
linked by a carbon chain containing aromatic rings · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2024002367A1 cover?
- The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
- Who is the assignee on this patent?
- Gilead Sciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D403/10. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Jan 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).